Comparison of baseline clinical characteristics between the entire study population and patients with evaluable GEP data
| Characteristic . | Entire cohort . | R-CHOP-treated patients . | ||||
|---|---|---|---|---|---|---|
| ALL . | With GEP data (DLBCL90) . | P . | ALL . | With GEP data (DLBCL90) . | P . | |
| Total (n) | 1149 | 804 | 866 | 629 | ||
| Age, median (range, y) | 69 (19-96) | 69 (20-96) | .36 | 66 (19-93) | 66 (20-93) | .72 |
| Age > 60 y (n, %) | 824 (72) | 565 (70) | .51 | 573 (66) | 409 (65) | .66 |
| Female sex (n, %) | 500 (44) | 351 (44) | .96 | 381 (44) | 274 (44) | .87 |
| Stage (n, %) | .02 | .08 | ||||
| I/II | 436 (41) | 345 (46) | 369 (44) | 296 (49) | ||
| III/IV | 633 (59) | 402 (54) | 471 (56) | 313 (51) | ||
| NA | 80 | 57 | 26 | 20 | ||
| PS (n, %) | .07 | .15 | ||||
| 0-1 | 593 (57) | 447 (61) | 523 (64) | 403 (68) | ||
| 2-4 | 445 (43) | 280 (39) | 289 (36) | 188 (32) | ||
| NA | 111 | 77 | 54 | 38 | ||
| LDH (n, %) | .28 | .23 | ||||
| Normal | 467 (50) | 348 (53) | 386 (52) | 299 (55) | ||
| Elevated | 459 (50) | 305 (47) | 357 (48) | 240 (45) | ||
| NA | 223 | 151 | 123 | 90 | ||
| Extranodal sites (n, %) | .04 | .04 | ||||
| 0-1 | 800 (75) | 591 (79) | 633 (75) | 487 (80) | ||
| ≥2 | 269 (25) | 156 (21) | 207 (25) | 122 (20) | ||
| NA | 80 | 57 | 26 | 20 | ||
| B symptoms (n, %) | .16 | .21 | ||||
| No | 677 (64) | 502 (68) | 555 (66) | 422 (70) | ||
| Yes | 375 (36) | 240 (32) | 280 (34) | 184 (30) | ||
| NA | 97 | 62 | 31 | 23 | ||
| Bulky disease ≥10 cm (n, %) | .28 | .34 | ||||
| No | 727 (71) | 531 (73) | 567 (71) | 425 (73) | ||
| Yes | 296 (29) | 192 (27) | 237 (29) | 158 (27) | ||
| NA | 126 | 81 | 62 | 46 | ||
| IPI risk group (n, %) | .07 | .13 | ||||
| Low (0-1) | 272 (29) | 225 (34) | 247 (33) | 207 (38) | ||
| Low-intermediate (2) | 215 (23) | 157 (24) | 180 (24) | 134 (25) | ||
| High-intermediate (3) | 216 (23) | 141 (21) | 170 (23) | 113 (21) | ||
| High (4, 5) | 235 (25) | 136 (21) | 158 (21) | 92 (17) | ||
| NA | 211 | 145 | 111 | 83 | ||
| HGBCL-DH status | .93 | .95 | ||||
| Non-HGBCL-DH | 781 (92) | 700 (92) | 607 (92) | 553 (93) | ||
| HGBCL-DH-BCL2 | 53 (6) | 44 (6) | 42 (6) | 36 (6) | ||
| HGBCL-DH-BCL6 | 15 (2) | 14 (2) | 8 (1) | 8 (1) | ||
| NA | 300 | 46 | 209 | 32 | ||
| Treatment regimen (n, %) | .74 | |||||
| R-CHOP | 866 (79) | 629 (82) | ||||
| R-CHOP-HDMTX | 6 (0.5) | 4 (0.5) | ||||
| R-CEOP | 54 (5) | 38 (5) | ||||
| CEOP/CHOP∗ | 2 (0.2) | 0 | ||||
| Palliative | 158 (14) | 89 (12) | ||||
| Intensive | 7 (0.6) | 4 (0.5) | ||||
| Patient refused | 10 (0.9) | 7 (0.9) | ||||
| Unknown | 46 | 33 | ||||
| Characteristic . | Entire cohort . | R-CHOP-treated patients . | ||||
|---|---|---|---|---|---|---|
| ALL . | With GEP data (DLBCL90) . | P . | ALL . | With GEP data (DLBCL90) . | P . | |
| Total (n) | 1149 | 804 | 866 | 629 | ||
| Age, median (range, y) | 69 (19-96) | 69 (20-96) | .36 | 66 (19-93) | 66 (20-93) | .72 |
| Age > 60 y (n, %) | 824 (72) | 565 (70) | .51 | 573 (66) | 409 (65) | .66 |
| Female sex (n, %) | 500 (44) | 351 (44) | .96 | 381 (44) | 274 (44) | .87 |
| Stage (n, %) | .02 | .08 | ||||
| I/II | 436 (41) | 345 (46) | 369 (44) | 296 (49) | ||
| III/IV | 633 (59) | 402 (54) | 471 (56) | 313 (51) | ||
| NA | 80 | 57 | 26 | 20 | ||
| PS (n, %) | .07 | .15 | ||||
| 0-1 | 593 (57) | 447 (61) | 523 (64) | 403 (68) | ||
| 2-4 | 445 (43) | 280 (39) | 289 (36) | 188 (32) | ||
| NA | 111 | 77 | 54 | 38 | ||
| LDH (n, %) | .28 | .23 | ||||
| Normal | 467 (50) | 348 (53) | 386 (52) | 299 (55) | ||
| Elevated | 459 (50) | 305 (47) | 357 (48) | 240 (45) | ||
| NA | 223 | 151 | 123 | 90 | ||
| Extranodal sites (n, %) | .04 | .04 | ||||
| 0-1 | 800 (75) | 591 (79) | 633 (75) | 487 (80) | ||
| ≥2 | 269 (25) | 156 (21) | 207 (25) | 122 (20) | ||
| NA | 80 | 57 | 26 | 20 | ||
| B symptoms (n, %) | .16 | .21 | ||||
| No | 677 (64) | 502 (68) | 555 (66) | 422 (70) | ||
| Yes | 375 (36) | 240 (32) | 280 (34) | 184 (30) | ||
| NA | 97 | 62 | 31 | 23 | ||
| Bulky disease ≥10 cm (n, %) | .28 | .34 | ||||
| No | 727 (71) | 531 (73) | 567 (71) | 425 (73) | ||
| Yes | 296 (29) | 192 (27) | 237 (29) | 158 (27) | ||
| NA | 126 | 81 | 62 | 46 | ||
| IPI risk group (n, %) | .07 | .13 | ||||
| Low (0-1) | 272 (29) | 225 (34) | 247 (33) | 207 (38) | ||
| Low-intermediate (2) | 215 (23) | 157 (24) | 180 (24) | 134 (25) | ||
| High-intermediate (3) | 216 (23) | 141 (21) | 170 (23) | 113 (21) | ||
| High (4, 5) | 235 (25) | 136 (21) | 158 (21) | 92 (17) | ||
| NA | 211 | 145 | 111 | 83 | ||
| HGBCL-DH status | .93 | .95 | ||||
| Non-HGBCL-DH | 781 (92) | 700 (92) | 607 (92) | 553 (93) | ||
| HGBCL-DH-BCL2 | 53 (6) | 44 (6) | 42 (6) | 36 (6) | ||
| HGBCL-DH-BCL6 | 15 (2) | 14 (2) | 8 (1) | 8 (1) | ||
| NA | 300 | 46 | 209 | 32 | ||
| Treatment regimen (n, %) | .74 | |||||
| R-CHOP | 866 (79) | 629 (82) | ||||
| R-CHOP-HDMTX | 6 (0.5) | 4 (0.5) | ||||
| R-CEOP | 54 (5) | 38 (5) | ||||
| CEOP/CHOP∗ | 2 (0.2) | 0 | ||||
| Palliative | 158 (14) | 89 (12) | ||||
| Intensive | 7 (0.6) | 4 (0.5) | ||||
| Patient refused | 10 (0.9) | 7 (0.9) | ||||
| Unknown | 46 | 33 | ||||
P values derived from Fisher exact test except for median age where Mann-Whitney test was used. P < .05 have been highlighted in bold.
HDMTX, high-dose methotrexate; IPI, international prognostic index; LDH, lactate dehydrogenase; NA, not available; non-HGBCL-DH, no double-hit lymphoma; PS, performance status; R-CEOP, rituximab, cyclophosphamide, etoposide, vincristine, and prednisone.
Rituximab intentionally omitted.